GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK

Diabetes

Volumn 63, Issue 10, 2014, Pages 3346-3358

  Beiroa, Daniel ^a,b   Imbernon, Monica ^a,b   Gallego, Rosalía ^c   Senra, Ana ^a   Herranz, Daniel ^a,b   Villarroya, Francesc ^b,e   Serrano, Manuel ^d   Fernø, Johan ^f   Salvador, Javier ^b,g   Escalada, Javier ^b,g   Dieguez, Carlos ^a,b   Lopez, Miguel ^a,b   Frühbeck, Gema ^b,g   Nogueiras, Ruben ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY OF BERGEN   (Norway)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIRAGLUTIDE; METFORMIN; AMP ACTIVATED PROTEIN KINASE KINASE; AMP-ACTIVATED PROTEIN KINASE KINASE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; PROTEIN KINASE; VENOM;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; BROWN ADIPOSE TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; ENERGY EXPENDITURE; ENZYME ACTIVATION; FEMALE; FOOD INTAKE; HUMAN; HYPOTHALAMUS; HYPOTHALAMUS VENTROMEDIAL NUCLEUS; LONGITUDINAL STUDY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; RESTING ENERGY EXPENDITURE; THERMOGENESIS; TREATMENT OUTCOME; ANIMAL; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; EATING; ENERGY METABOLISM; METABOLISM; MIDDLE AGED; OBESITY; PHYSIOLOGY; VERY ELDERLY; YOUNG ADULT;

ADIPOSE TISSUE, BROWN; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; EATING; ENERGY METABOLISM; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; HYPOTHALAMUS; MALE; METFORMIN; MICE; MIDDLE AGED; OBESITY; PEPTIDES; PROTEIN KINASES; RATS; THERMOGENESIS; VENOMS; YOUNG ADULT;

EID: 84907495079     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0302     Document Type: Article

References (49)

1. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32
2. Göke R, Fehmann HC, Göke B. Glucagon-like peptide-1 (7-36) amide is a new incretin/enterogastrone candidate. Eur J Clin Invest 1991;21:135-144
3. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013;17:819-837
4. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-1304
5. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987;79:616-619
6. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1) -(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996;81:327-332
7. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72
8. Shimizu I, Hirota M, Ohboshi C, Shima K. Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 1987;121: 1076-1082
9. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995;7:2294-2300
10. Skibicka KP, Alhadeff AL, Grill HJ. Hindbrain cocaine- and amphetamine-regulated transcript induces hypothermia mediated by GLP-1 receptors. J Neurosci 2009;29:6973-6981
11. Holst JJ. Incretin hormones and the satiation signal. Int J Obes (Lond) 2013; 37:1161-1168
12. Tang-Christensen M, Larsen PJ, Göke R, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271:R848-R856
13. Seo S, Ju S, Chung H, Lee D, Park S. Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. Endocr J 2008;55:867-874
14. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 2008;57:2046-2054
15. Kinzig KP, D'Alessio DA, Herman JP, et al. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors [published correction appears in J Neurosci 2003;23:8158], J Neurosci 2003;23:6163-6170
16. Kinzig KP, D'Alessio DA, Seeley RJ. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 2002;22:10470-10476
17. Nogueiras R, Pérez-Tilve D, Veyrat-Durebex C, et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci 2009;29:5916-5925
18. Lockie SH, Heppner KM, Chaudhary N, et al. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes 2012;61:2753-2762
19. Marre M, Shaw J, Brandie M, et al.; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278
20. Astrup A, Rössner S, Van Gaal L, et al.; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-1616
21. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30
22. Imbernon M, Beiroa D, Vazquez MJ, et al. Central melanin-concentrating hormone influences liver and adipose metabolism via specific hypothalamic nuclei and efferent autonomic/JNK1 pathways. Gastroenterology 2013;144:636-649
23. López M, Lelliott CJ, Tovar S, et al. Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. Diabetes 2006;55:1327-1336
24. Czyzyk TA, Romero-Picó A, Pintar J, et al. Mice lacking δ-opioid receptors resist the development of diet-induced obesity. FASEB J 2012;26:3483-3492
25. López M, Varela L, Vázquez MJ, et al. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 2010;16: 1001-1008
26. Martinez de Morentin PB, Whittle AJ, Fernø J, et al. Nicotine induces negative energy balance through hypothalamic AMP-activated protein kinase. Diabetes 2012;61:807-817
27. Moreno-Navarrete JM, Catalán V, Ortega F, et al. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010;7:27
28. Frühbeck G, Alonso R, Marzo F, Santidrián S. A modified method for the indirect quantitative analysis of phytate in foodstuffs. Anal Biochem 1995;225: 206-212
29. Johansson G, Westerterp KR. Assessment of the physical activity level with two questions: validation with doubly labeled water. Int J Obes (Lond) 2008;32: 1031-1033
30. Catalán V, Gómez-Ambrosi J, Ramirez B, et al. Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg 2007; 17:1464-1474
31. Barrera JG, D'Alessio DA, Drucker DJ, Woods SC, Seeley RJ. Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes 2009;58:2820-2827
32. Hwa JJ, Ghibaudi L, Williams P, Witten MB, Tedesco R, Strader CD. Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation. Peptides 1998;19:869-875
33. Velásquez DA, Martínez G, Romero A, et al. The central Sirtuin 1/p53 pathway is essential for the orexigenic action of ghrelin. Diabetes 2011;60:1177-1185
34. Riediger T, Eisele N, Scheel C, Lutz TA. Effects of glucagon-like peptide 1 and oxyntomodulin on neuronal activity of ghrelin-sensitive neurons in the hypothalamic arcuate nucleus. Am J Physiol Regul Integr Comp Physiol 2010;298: R1061-R1067
35. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschöp MH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci USA 2008;105:9793-9798
36. Shughrue PJ, Lane MV, Merchenthaler I. Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 1996;137:5159-5162
37. Buse JB, Rosenstock J, Sesti G, et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374:39-47
38. Garber A, Henry R, Ratner R, et al.; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373: 473-481
39. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001;50:2530-2539
40. Kotz CM, Grace MK, Briggs J, Levine AS, Billington CJ. Effects of opioid antagonists naloxone and naltrexone on neuropeptide Y-induced feeding and brown fat thermogenesis in the rat. Neural site of action. J Clin Invest 1995;96: 163-170
41. Uno T, Shibata M. Role of inferior olive and thoracic IML neurons in nonshivering thermogenesis in rats. Am J Physiol Regul Integr Comp Physiol 2001; 280:R536-R546
42. Wu J, Boström P, Sparks LM, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 2012;150:366-376
43. Virtanen KA, Lidell ME, Drava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med 2009;360:1518-1525
44. Cypess AM, Lehman S, Williams G, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009;360:1509-1517
45. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med 2009;360:1500-1508
46. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004; 27:1915-1921
47. Bradley DP, Kulstad R, Racine N, Shenker Y, Meredith M, Schoeller DA. Alterations in energy balance following exenatide administration. Appl Physiol Nutr Metab 2012;37:893-899
48. Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 2012;97:258-266
49. Tan TM, Field BC, McCullough KA, et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy ex-penditure and amelioration of hyperglycemia. Diabetes 2013;62:1131-1138